Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Barr Laboratories, a subsidiary of Barr Pharmaceuticals, has received final approval from the FDA for its abbreviated new drug application to manufacture and market drospirenone and ethinyl estradiol.
Subscribe to our email newsletter
Drospirenone and ethinyl estradiol product is a generic version of Yasmin, an oral contraceptive product manufactured and marketed by Bayer Schering Pharma.
Yasmin is a 28-day oral contraceptive consisting of 21 active tablets each containing 3mg of drospirenone and 0.03mg of ethinyl estradiol and seven inert tablets. Yasmin is indicated for the prevention of pregnancy in women who elect to use an oral contraceptive.